|Payment & Shipping Terms ||Supply Capacity |
|Unit Price:||160.0~290.0 USD||Production Capacity:||100000L/WEEK|
|Payment Terms:||WU, Money Gram, T/T, bitcoin||Packing:||brand new|
|Min. Order:||100 ml||Delivery Date:||with 6 working hours|
|Means of Transport:||Air|
CAS No.: 388082-78-8
Other Names: Lapatinib ditosylate hydrate
EINECS No.: 388082-78-8
Place of Origin: Shanghai, China (Mainland)
Type: Antineoplastic Agents
Grade Standard: Medicine Grade
Usage: Animal Pharmaceuticals
Appearance: White Powder
Application: API Used for the treatment of breast cancer.
The COA of this product :
|Appearance||Off-white or white powder||Conforms|
|Related substances||Individual impurity≤0.5%||0.09%|
|Loss on drying||≤0.5%||0.3%|
|Residue on ignition||≤0.1%||0.04%|
Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal receptor (EGFR) pathways.
It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).
1) Lapatinib is a breast cancer targeted therapy drug . Breast cancer molecular targeted therapy aims at the occurrence and development of cancer-related genes and their expression products of breast cancer for treatment. Molecular targeted drug by blocking signal transduction of tumor cells or associated cells , control changes in cell gene expression, in order to inhibit or kill tumor cells.
2) Lapatinib is a novel targeted anti-cancer drug. It Can act on Her-1 and Her-2 two targets at he same time, the biological effect of the inhibition of tumor cell proliferation and growth arising from this mode of action is much larger than acting on just one target. The so-called targeted therapy, refers to certain receptors, genes or proteins as a key target, and then targets to kill tumor cells related to drug.
Lapatinib ditosylate COA
|Description||Light yellow or almost white crystalline powder||Light Yellow powder|
|Loss On Drying||0.5%max||0.25%|
|Residue On Ignition||0.1%max||0.05%|
|Heavy Metals||20PPm max||<20PPm|
|Organic Volatile Impurities||Meets the requirement.||Conforms|
|Single Impurity: 1.0%max||<1.0%|
|Total Impurities: 2.0%max||<2.0%|
|Conclusion||The specification conforms to enterprise standard.|
Category: Other pharmaceuticals
Related Category: antibiotics